Vera Therapeutics IncNASDAQ VERA Stock Report

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 41 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The company is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The firm is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).